123 related articles for article (PubMed ID: 7774654)
1. Covalent linkage of C3 to properdin during complement activation.
Whiteman LY; Purkall DB; Ruddy S
Eur J Immunol; 1995 May; 25(5):1481-4. PubMed ID: 7774654
[TBL] [Abstract][Full Text] [Related]
2. Formation of covalently linked C3-C3 dimers on IgG immune aggregates.
Barrio E; Antón LC; Marqués G; Sánchez A; Vivanco F
Eur J Immunol; 1991 Feb; 21(2):343-9. PubMed ID: 1999223
[TBL] [Abstract][Full Text] [Related]
3. A covalent dimer of complement C4b serves as a subunit of a novel C5 convertase that involves no C3 derivatives.
Masaki T; Matsumoto M; Yasuda R; Levine RP; Kitamura H; Seya T
J Immunol; 1991 Aug; 147(3):927-32. PubMed ID: 1861081
[TBL] [Abstract][Full Text] [Related]
4. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates.
Antón LC; Ruiz S; Barrio E; Marqués G; Sánchez A; Vivanco F
Eur J Immunol; 1994 Mar; 24(3):599-604. PubMed ID: 8125130
[TBL] [Abstract][Full Text] [Related]
5. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
Mayes JT; Schreiber RD; Cooper NR
J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
[TBL] [Abstract][Full Text] [Related]
6. Association of activated properdin with complexes of properdin with C3.
Whiteman LY; Purkall DB; Ruddy S
J Immunol; 1991 Aug; 147(4):1344-51. PubMed ID: 1869827
[TBL] [Abstract][Full Text] [Related]
7. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
Vogt W; Schmidt G; Lynen R; Dieminger L
J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
[TBL] [Abstract][Full Text] [Related]
9. Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates.
Takata Y; Tamura N; Fujita T
J Immunol; 1984 May; 132(5):2531-7. PubMed ID: 6232320
[TBL] [Abstract][Full Text] [Related]
10. Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway.
Brade V; Bentley C; Bitter-Suermann D; Hadding U
Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):402-14. PubMed ID: 556571
[TBL] [Abstract][Full Text] [Related]
11. The effect of anticomplementary substances on properdin in normal and C2-deficient sera.
McLean RH; Townsend K; Michael AF
Clin Exp Immunol; 1975 Mar; 19(3):435-44. PubMed ID: 1204244
[TBL] [Abstract][Full Text] [Related]
12. Prevention of immune precipitation by purified components of the alternative pathway.
Naama JK; Holme E; Hamilton E; Whaley K
Clin Exp Immunol; 1985 Apr; 60(1):169-77. PubMed ID: 3159522
[TBL] [Abstract][Full Text] [Related]
13. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
Mold C; Nemerow GR; Bradt BM; Cooper NR
J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
Sahu A; Kay BK; Lambris JD
J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
[TBL] [Abstract][Full Text] [Related]
15. Alternative pathway of complement: nonenzymatic, reversible transition of precursor to active properdin.
Götze O; Medicus RG; Müller-Eberhard HJ
J Immunol; 1977 Feb; 118(2):525-32. PubMed ID: 839069
[TBL] [Abstract][Full Text] [Related]
16. Complement activation in semisolid media: insolubilization of alternative pathway convertases in agar gels with C3 nephritic factor-containing sera.
Arnaout MA; Davis AE; Rosen RS; Alper CA
J Immunol; 1977 Oct; 119(4):1316-20. PubMed ID: 894039
[TBL] [Abstract][Full Text] [Related]
17. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
[TBL] [Abstract][Full Text] [Related]
19. Complement activation in semi-solid medium: Insolubilization of properdin and the third component of complement (C3) in agar gels.
Ziegler JB; Watson L; Goodkofsky I; Alper CA; Lepow IH
J Immunol; 1976 Jan; 116(1):75-9. PubMed ID: 812917
[TBL] [Abstract][Full Text] [Related]
20. An inherited deficiency of the third component of complement, C3, in guinea pigs.
Burger R; Gordon J; Stevenson G; Ramadori G; Zanker B; Hadding U; Bitter-Suermann D
Eur J Immunol; 1986 Jan; 16(1):7-11. PubMed ID: 3512275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
